Abstract: Provided are compounds which are Spt5 inhibitors and which are for use in the treatment diseases and disorders in which inhibiting one or more activities of Spt5 is beneficial, such as, for example, Trinucleotide repeat disorders, obesity, inflammatory diseases, infectious diseases and cancer. The compounds are represented by Formulae I-VII, as defined in the specification.

Abstract: Methods of inhibiting eIF4G1 binding to eIF1, and inhibiting translation initiation are provided. Pharmaceutical compositions comprising inhibitors of eIF4G1-eIF1 binding and there use in treating disease are also provided.

Abstract: Provided are compounds which are Spt5 inhibitors and which are for use in the treatment diseases and disorders in which inhibiting one or more activities of Spt5 is beneficial, such as, for example, Trinucleotide repeat disorders, obesity, inflammatory diseases, infectious diseases and cancer. The compounds are represented by Formulae I-VII, as defined in the specification.

Abstract: The invention provides methods and compositions relating to human tata-binding protein associated factor 105 (hTAF.sub.II 105) and related nucleic acids. The proteins may be produced recombinantly from transformed host cells from the disclosed hTAF.sub.II 105 encoding nucleic acids or purified from human cells. The invention provides isolated hTAF.sub.II 105 hybridization probes and primers capable of specifically hybridizing with the disclosed hTAF.sub.II 105 gene, hTAF.sub.II 105-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.